Antimicrobial Peptides in Melanoma: Present but Not Driving Tumor Aggressiveness

What the researchers found

Melanoma cells expressed variable levels of antimicrobial peptide mRNA, with LL-37 (cathelicidin) generally increased and hBD-4 (β-defensin 4) decreased in most melanoma cell lines compared to primary uveal melanocytes. However, neither HNP-1 (α-defensin) nor LL-37 had an observable influence on tumor cell migration in scratch assays.

Aggressive cutaneous melanoma cells exhibited vasculogenic mimicry (forming blood vessel-like channels) in 3D culture, but AMP exposure did not alter this process. Overall, despite altered expression patterns, antimicrobial peptides had little influence on the major characteristics contributing to melanoma aggressiveness and progression.

Why it matters

There has been growing interest in repurposing antimicrobial peptides as cancer therapies or understanding their role in tumor biology. This study provides an important negative result: while AMPs are expressed by melanoma cells with altered patterns, they do not appear to drive key aggressive behaviors. This helps narrow the focus of AMP-cancer research and prevents wasted effort on approaches unlikely to yield therapeutic benefit in melanoma.

How the study worked

AMP mRNA expression (HNP-1, LL-37, hBD-1 through hBD-4) was measured by RT-PCR in human uveal and cutaneous melanoma cell lines, primary uveal melanocytes, and primary uveal melanoma cells. Cell migration was assessed using an in vitro scratch assay with custom Matlab analysis. Vasculogenic mimicry was evaluated in 3D cultures using light and fluorescence microscopy.

What this study cannot tell us

This was an in vitro study limited to cell lines and primary cultures, which may not fully represent AMP behavior in the complex tumor microenvironment in vivo. Only mRNA expression was measured (not protein levels), and only two AMPs (HNP-1 and LL-37) were functionally tested for migration effects. The study examined limited aspects of tumor biology — other AMP roles such as immune modulation were not assessed.

How to read the evidence

This is an in vitro laboratory study using cell lines and primary cultures. While the methodology is sound (RT-PCR, scratch assays, 3D culture), the negative functional results are limited to two AMPs and specific assays, and findings may not reflect in vivo tumor biology.

When this study was published

Published in 2017, this study addressed a question that remains relevant as AMP-based cancer therapies continue to be explored. The negative result provides a useful boundary for the field.

The bigger picture

Antimicrobial peptides have dual roles in cancer — some promote tumor growth while others have antitumor effects. This study helps clarify that in melanoma specifically, AMPs don't appear to be major players in tumor aggressiveness. This is a useful data point in the larger effort to understand which cancer types might actually benefit from AMP-based therapies and which would not.

Questions still open

• Do AMPs play a more significant role in melanoma biology in vivo, where the tumor microenvironment and immune cells are present?
• Could the altered AMP expression patterns in melanoma reflect immune evasion strategies rather than direct effects on tumor cell behavior?
• Would AMP protein levels tell a different story than the mRNA expression measured in this study?

Common questions

Read the original research

Expression of Antimicrobial Peptides by Uveal and Cutaneous Melanoma Cells and Investigation of Their Role in Tumor Cell Migration and Vasculogenic Mimicry.

Current eye research, 42(11), 1474-1481

Citation

Manarang, Joseph C; Otteson, Deborah C; McDermott, Alison M. (2017). Expression of Antimicrobial Peptides by Uveal and Cutaneous Melanoma Cells and Investigation of Their Role in Tumor Cell Migration and Vasculogenic Mimicry.. Current eye research, 42(11), 1474-1481. https://doi.org/10.1080/02713683.2017.1339806